 | |
| Clinical data | |
|---|---|
| Trade names | Gastrozepin |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.044.739 |
| Chemical and physical data | |
| Formula | C19H21N5O2 |
| Molar mass | 351.410 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pirenzepine (Gastrozepin), anM1 selective antagonist, is used in the treatment ofpeptic ulcers, as it reducesgastric acid secretion and reducesmuscle spasm. It is in a class of drugs known asmuscarinic receptor antagonists;acetylcholine is the neurotransmitter of theparasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through theblood–brain barrier.
Pirenzepine has been investigated for use inmyopia control.[2][3]
It promotes the homodimerization oroligomerisation ofM1 receptors.[4]
